SCHEMBL5477776

SCHEMBL5477776

COc1cc2c(cc1OC(F)F)[C@H]1C[C@H](O)CC[C@H]1N=C2c1ccc(C(=O)NC2CC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 2/20 0.43
PDE4B Q07343 2/20 0.43
PDE4A P27815 1/20 0.43
PDE4C Q08493 1/20 0.43
MAPK14 Q16539 3/20 0.40
FYN P06241 2/20 0.40
TNF P01375 1/20 0.37
SIK1 P57059 3/20 0.36
SIK2 Q9H0K1 3/20 0.36
SIK3 Q9Y2K2 3/20 0.36
ROCK2 O75116 2/20 0.36
BMPR1B O00238 1/20 0.36
GAK O14976 1/20 0.36
RIPK2 O43353 1/20 0.36
ABL1 P00519 1/20 0.36
LCK P06239 1/20 0.36
CSF1R P07333 1/20 0.36
YES1 P07947 1/20 0.36
LYN P07948 1/20 0.36
HCK P08631 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5479033 1.00 PDE4D (0.43) PDE4DPDE4BPDE4APDE4CMAPK14
SCHEMBL5479681 1.00 PDE4D (0.43) PDE4DPDE4BPDE4APDE4CMAPK14
SCHEMBL5477321 0.94 PDE4D (0.46) PDE4DPDE4BPDE4APDE4CMAPK14
SCHEMBL5473831 0.88 PDE4D (0.54) PDE4DPDE4BPDE4APDE4CMAPK14
SCHEMBL5480706 0.86 PDE4D (0.50) PDE4DPDE4BPDE4APDE4CFYN
SCHEMBL5478618 0.85 PDE4D (0.53) PDE4DPDE4BPDE4APDE4CMAPK14
SCHEMBL5476150 0.84 PDE4D (0.46) PDE4DPDE4BPDE4APDE4CROCK2
SCHEMBL5477971 0.84 PDE4D (0.48) PDE4DPDE4BPDE4APDE4C
SCHEMBL5476753 0.84 CD274 (0.50) PDE4DPDE4BPDE4APDE4CSIK1
SCHEMBL5473560 0.82 CYP2D6 (0.50) PDE4DPDE4BPDE4APDE4CMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors ALTANA PHARMA AG (DE) 2007-08-09 US claimed
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors ALTANA PHARMA AG (DE) 2007-08-09 US disclosed
EP-1725534-A1 NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP disclosed
WO-2005087745-A1 NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors PDE4A, PDE4B, PDE4C PDE4D 4/4885PDE4B 2/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.